Research article

Neutrophils exhibit distinct phenotypes toward chitosans with different degrees of deacetylation: implications for cartilage repair

Pascale Simard¹,²*, Hugo Galarneau¹*, Sébastien Marois¹, Daniel Rusu¹,³, Caroline D Hoemann⁴, Patrice E Poubelle¹,³, Hani El-Gabalawy⁵ and Maria JG Fernandes¹,²

¹Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du CHUQ-CHUL, boul. Laurier, Québec, G1V 4G2, Canada
²Department of Anatomy and Physiology, Université Laval, avenue de la Médecine, Québec, G1V 0A6, Canada
³Department of Medicine, Université Laval, avenue de la Médecine, Québec, G1V 0A6, Canada
⁴Department of Chemical Engineering, Institute of Biomedical Engineering, École Polytechnique, boul. Édouard-Montpetit, Montréal, H3C 3A7, Canada
⁵Arthritis Centre, University of Manitoba, Sherbrook Street, Winnipeg, R3A 1M4, Canada

* Contributed equally

Corresponding author: Maria JG Fernandes, maria.fernandes@crchul.ulaval.ca

Received: 22 Sep 2008 Revisions requested: 17 Nov 2008 Revisions received: 23 Feb 2009 Accepted: 21 May 2009 Published: 21 May 2009

Arthritis Research & Therapy 2009, 11:R74 (doi:10.1186/ar2703)
This article is online at: http://arthritis-research.com/content/11/3/R74

© 2009 Simard et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Osteoarthritis is characterized by the progressive destruction of cartilage in the articular joints. Novel therapies that promote resurfacing of exposed bone in focal areas are of interest in osteoarthritis because they may delay the progression of this disabling disease in patients who develop focal lesions. Recently, the addition of 80% deacetylated chitosan to cartilage microfractures was shown to promote the regeneration of hyaline cartilage. The molecular mechanisms by which chitosan promotes cartilage regeneration remain unknown. Because neutrophils are transiently recruited to the microfracture site, the effect of 80% deacetylated chitosan on the function of neutrophils was investigated. Most studies on neutrophils use preparations of chitosan with an uncertain degree of deacetylation. For therapeutic purposes, it is of interest to determine whether the degree of deacetylation influences the response of neutrophils to chitosan. The effect of 95% deacetylated chitosan on the function of neutrophils was therefore also investigated and compared with that of 80% deacetylated chitosan.

Methods Human blood neutrophils from healthy donors were isolated by centrifugation on Ficoll-Paque. Chemotaxis was performed using the chemoTX system. Production of superoxide anions was evaluated using the cytochrome c reduction assay. Degranulation was determined by evaluating the release of myeloperoxidase and lactoferrin. The internalization of fluorescently labelled 80% deacetylated chitosan by neutrophils was studied by confocal microscopy.

Results Neutrophils were dose dependently attracted to 80% deacetylated chitosan. In contrast, 95% deacetylated chitosan was not chemotactic for neutrophils. Moreover, the majority of the chemotactic effect of 80% deacetylated chitosan was mediated by phospholipase-A₂-derived bioactive lipids. Contrary to the induction of chemotaxis, neither 80% nor 95% deacetylated chitosan activated the release of granule enzymes or the generation of active oxygen species. Despite the distinct response of neutrophils toward 80% and 95% deacetylated chitosan, both chitosans were internalized by neutrophils.

Conclusions Eighty per cent deacetylated chitosan induces a phenotype in neutrophils that is distinct from the classical phenotype induced by pro-inflammatory agents. Our observations also indicate that the degree of deacetylation is an important factor to consider in the use of chitosan as an accelerator of repair because neutrophils do not respond to 95% deacetylated chitosan.

80 M: 80% deacetylated chitosan of medium viscosity; 95 M: 95% deacetylated chitosan of medium viscosity; cPLA₂-α: cytosolic phospholipase A₂-α; DDA: degree of deacetylation; FBS: fetal bovine serum; fMLP: N-formyl-methionyl-leucyl-phenylalanine; HTAB: hexadecyltrimethylammonium bromide; LTB₄: leukotriene B₄; MPO: myeloperoxidase; OA: osteoarthritis; PAF: platelet-activating factor; PDI: polydispersity index; PMN: polymorphonuclear neutrophil; RITC: rhodamine B isothiocyanate.
**Introduction**

Osteoarthritis (OA) is characterized by progressive destruction of cartilage in the articular joints [1]. Because it is one of the main causes of disability, this form of arthritis is a burden to both society and the patient. The incidence of OA increases with age. Over 80% of the elderly population exhibits radiographic evidence of OA.

Focal cartilage lesions in humans can be treated by microfracture. This resurfacing procedure, when successful, can re-stabilize the joint and slow the progression of OA. Chitosan was recently shown to promote the regeneration of articular cartilage and to slow the progression of OA. Chitosan was shown to facilitate cartilage repair through the application of an in situ solidifying chitosan-glycerol phosphate/blood clot over lesions treated with microfracture [2,3]. Chitosan-glycerol phosphate/blood clots represent a novel articular cartilage repair approach, which has yielded promising results in the clinic [4].

Chitosan is a linear polymer of β(1→4)-linked glucosamine and N-acetyl-D-glucosamine residues obtained by the N-deacetylation of chitin. Chitosan is biodegradable, non-toxic, and nonimmunogenic [5-7]. The degree of deacetylation (DDA) influences the physical properties of chitosan. As the degree of deacetylation increases, the degree of solubility of chitosan in different solvents decreases and susceptibility to lysoosomal biodegradation decreases [8,9]. The chitosan used in the cartilage repair model is of medium viscosity and is 80% deacetylated (80 M). In vivo, 50% to 80% deacetylated chitosan is slowly degraded and eventually cleared by enzymatic and cell-based mechanisms [5,10].

The presence of 80 M chitosan over repairing microfracture or microdrill holes is associated with the recruitment of polymorphonuclear neutrophils (PMNs) to the granulation tissue as well as remodeling and revascularization of the damaged trabecular bone, and subsequent formation of more hyaline repair tissue in both rabbit and sheep repair models [2,3,11]. In contrast, few PMNs home to microdrills in the absence of chitosan [11]. Remarkably, PMNs persist in repairing defects for several weeks, in parallel with clearance of the 80 M chitosan [11]. Furthermore, 80 M chitosan, termed 80 M, and 95 M chitosan, termed 95 M, are deacetylated (80% or 95%) chitosan. In vivo, 50% to 80% deacetylated chitosan is slowly degraded and eventually cleared by enzymatic and cell-based mechanisms [5,10].

To identify the mechanisms through which 80 M chitosan promotes cartilage regeneration in this repair model, the first objective of the present study was to investigate the effect of 80 M chitosan on the function of PMNs. Even though the response of PMNs toward chitosan has been characterized in vitro to some extent [12-16], it remains difficult to compare the results between studies and to draw clear conclusions because the chitosan preparations in most studies vary and details on the quality of the chitosan preparations are rarely provided. With regard to the latter, the presence of endotoxins is an important consideration when investigating PMN responses. In the present study, chitosan preparations of medical grade were used. Regarding the former, some studies use chitosan preparations of unspecified DDA whereas other studies use water-soluble chitosan, which does not form a solid implant [16] or semi-crystalline scaffolds [10]. This complicates the interpretation of the results because the degree of DDA is a determining factor for the physical properties of chitosan, and it is not yet established to what extent PMNs respond differently to chitosans of different DDA. Also, it remains to be determined whether the PMN response varies toward chitosan presented as a particulate or a cross-linked scaffold. To optimize the use of chitosan in clinical applications, it is therefore critical to address the effect of DDA on the ability of chitosan to activate PMNs and to compare different preparations of chitosan (for instance, chitosan suspensions versus scaffolds). The second objective of this study was therefore to compare the response of PMNs to two chitosan preparations of a defined DDA, namely 80 M chitosan and 95 M chitosan. The 95 M chitosan was investigated because our preliminary results indicate that PMNs respond differently to chitosan of this DDA in vivo.

**Materials and methods**

All preparation and incubation procedures were performed under sterile conditions.

**Materials**

The two medical grade chitosan preparations (80.6% or 94.6% DDA) used in this study are certified to contain under 0.2% weight/weight protein, <500 EU/g endotoxin, and <10 parts/million heavy metals. To prevent contamination by endotoxin of chitosan solutions, chitosan powder was dissolved in double-distilled water filtered by MilliQ (Millipore, Billerica, MA, USA), at a resistance below 18.2 MΩ cm and levels of trace organic compounds below 30 parts/billion with certified 1.0 N HCl, using heat-treated endotoxin-free glassware and stir bars. Chitosan solutions were manipulated under aseptic conditions with laminar flow hoods and dispensed in sterile cryovials with cryo-resistance silicone gaskets for storage at -80°C. The chitosan solutions are of medium viscosity of 1,422 mPa.S for 80% DDA chitosan, termed 80 M (Mn = 176 kDa, polydispersity index [PDI] = 1.4), or 2,964 mPa.S for 95% DDA chitosan, termed 95 M (Mn = 147 kDa, PDI = 1.6), as previously described by Ma and coworkers [17]. Chitosan solutions were further diluted with sterile double-distilled water to 5 mg/ml or 0.5 mg/ml stock solutions. The DDA of chitosan was provided by the certificates of analysis from the supplier (Bio Syntech Canada Inc., Laval, QC, Canada).

Rhodamine B isothiocyanate (RITC) was covalently conjugated with each chitosan (RITC-chitosan) to generate either RITC-80 M (80% DDA, number average molecular weight Mn = 144 kDa, PDI = 1.3, 0.5% mol/mol RITC/chitosan) or RITC-
95 M (95% DDA, Mn = 177 kDa, PDI = 1.1, 0.6% mol/mol RITC/chitosan). The DDA of RITC-chitosan derivatives is reported as unchanged, given that the derivatization level was determined as only 0.5% mol RITC/mol chitosan (as reported by Ma and coworkers [17]). Ficoll-Paque and dextran used for the isolation of PMN were obtained from Pharmacia (Kirkland, Québec, Canada) and fetal bovine serum (FBS) as well as RPMI 1640 were purchased from Wisent (St-Bruno, Québec, Canada). Calcein/AM was obtained from Invitrogen (Burlington, Ontario, Canada). Migration was assessed using the ChemoTx system from Neuroprobe (Gaithersburg, MD, USA) and the purified myeloperoxidase (MPO), O-dianisidine dihydrochloride, hydrogen peroxide, and cytochalasin B used in the MPO assay were obtained from Sigma-Aldrich (Oakville, Ontario, Canada). Hexadecyltrimethylammonium bromide (HTAB) was purchased from Fluka Chemie GmbH (Buchs, Switzerland). Cytochrome c equine heart and pyrrolidine-1 were purchased from Calbiochem (Gibbstown, New Jersey, USA).

Isolation of polymophonuclear neutrophils
The Institutional Review Board of the Université Laval (Québec, QC, Canada) approved the study, and volunteers signed a consent form. PMNs were isolated as previously described [18]. Briefly, venous blood was obtained from healthy adult volunteers, in accordance with institute-approved protocols, in tubes containing heparin or isocitrate. No difference was observed between the results obtained with these two anticoagulants. After sedimentation of red blood cells in 2% dextran, PMNs were aseptically purified by centrifugation on Ficoll-Paque cushions. Contaminating erythrocytes were removed by hypotonic lysis and PMNs were resuspended in RPMI 1640 supplemented with 0.1% FBS previously decompartmented at 56°C for 30 minutes, except for the chemotaxis experiment (10% decompartmented FBS).

Chemotaxis
Chemotaxis was measured as described previously [13]. Briefly, PMNs were resuspended in RPMI-1640 and 10% FBS at a concentration of 10^7 cells/ml and were pre-incubated with 1 μg/ml calcein/AM at 37°C for 30 minutes in the dark with constant agitation. Cells were washed twice and resuspended in RPMI/10% FBS at 5 × 10^7 cells/ml at 37°C. PMN migration was monitored using a 96-well ChemoTx disposable chemotaxis system. The fluorescence of cells in the filters was measured using a microplate fluorescence reader (FL600; Bio-Tek Instruments, Winooski, VT, USA; excitation wavelength 485 nm, emission wavelength 530 nm). Fluorescence was converted to numbers of PMNs based on a standard curve generated by seeding known numbers of PMNs in the bottom of the chamber. The results are expressed as percentage of migrated cells, calculated as the fluorescence of migrated PMNs/fluorescence of 20,000 PMNs/ml × 100, obtained from the standard curve. In some experiments, PMNs were incubated with a final concentration of 0.5 μg/ml pertussis toxin for 90 minutes or with 10^-7 mol/l pyrrolidine-1 for 10 minutes at 37°C before the chemotaxis assay.

Production of superoxide anions by polymphonuclear neutrophils
Superoxide anion production in response to 80 M and 95 M chitosan was determined using the cytochrome c reduction assay, as previously described [19]. Briefly, freshly isolated PMNs were resuspended at a concentration of 1 × 10^6 cells/ml in RPMI supplemented with 0.1% decompartmented FBS and cytochrome c at a final concentration of 125 μg/ml. The cells were incubated at 37°C for 5 minutes before the addition of the indicated concentrations of 80 M or 95 M chitosan. Cells were incubated for an additional 10 minutes at 37°C and the reaction stopped on ice for 10 minutes. The samples were then centrifuged at 12,000 g for 2 minutes at 4°C and the optical density of the supernatants was read at 540, 550, and 560 nm in a spectrophotometer (Milton Roy Spectronic 1001 Plus spectrophotometer, Milton Roy, Rochester, NY, USA). The amount of superoxide produced was calculated using the following formula: A_{550} - (A_{540} + A_{560})/2. The absorbance was transformed into the amount of superoxide produced (nmol/10^6 neutrophils) by using a conversion factor of 47.4, derived from the molar extinction coefficient of cytochrome c.

Release of myeloperoxidase and lactoferrin by polymphonuclear neutrophils
Degranulation was determined using the MPO and lactoferrin assay, as described by Bradley and coworkers [20] and Mocsai and colleagues [21], respectively.

For the MPO assay, PMNs (10^-7 cells/ml) were incubated with 10 μmol/l cytochalasin B, an actin depolymerizing agent that is known to amplify granule exocytosis, for 2 minutes at 37°C and then with the indicated concentrations of 80 M or 95 M chitosan for 30 minutes at 37°C. A negative control with cytochalasin B and a positive control with cytochalasin B + N-formyl-methionyl-leucyl-phenylalanine (fMLP; 5 minutes incubation) were also performed. PMNs were then centrifuged for 1 minute at 12,000 g and lysed in HTAB lysis buffer (0.5% HTAB, 50 mmol/l K2HPO4 buffer [pH 6.0]). One hundred microliters of the lysate and cell pellet was mixed with 2.4 ml of a K2HPO4 buffer (50 mmol/l phosphate buffer [pH 6.0], 0.2 mg/ml o-dianisidine dihydrochloride, and 0.003% hydrogen peroxide) before reading the optical density at 460 nm in a spectrophotometer (Milton Roy Spectronic 1001 Plus spectrophotometer). Purified human MPO (from 0.0625 to 1 U) was used to generate a standard curve. The value % release of MPO’ corresponds to the ratio of the amount of MPO released/the total amount of released and cellular MPO.

For the lactoferrin assay, PMNs (5 × 10^6 cells/ml) were incubated as described above for the MPO experiments. The release of lactoferrin was determined by enzyme-linked immunoresorbant assay [21]. Supernatants were diluted 10-fold and
100-fold in 50 mmol/l CO₂/HCO₃ buffer (pH 9.6) and 100 µl of the diluted supernatants or of known concentrations of human lactoferrin were added to 96-microwell plates (Nalge Nunc International, Rochester, NY, USA) and incubated overnight at 4°C. Nonspecific binding sites were blocked with phosphate-buffered saline supplemented with 0.5% bovine serum albumin and 0.5% Tween-20 overnight at room temperature. One hundred microliters of rabbit anti-human lactoferrin antibody (1:500 dilution of 17.05 mg/ml stock) was then added to each well and incubated for 2 hours. One hundred microliters of the secondary antibody, peroxidase-conjugated anti-rabbit antibody (1:40,000 dilution), was then added and incubated for 30 minutes. Each of the above steps was performed at room temperature and between each step the plates were repeatedly washed with 1× Tris-buffered saline/0.1% Tween-20. Tetra-methyl-benzidine was added before stopping the reaction with 50 µl of 1 mol/l sulfuric acid. Absorbance was read at 450 nm with a microplate reader, and the lactoferrin concentration was calculated using the standard curve.

Internalization of 80 M and 95 M chitosan by polymorphonuclear neutrophils

Freshly isolated PMNs were resuspended in RPMI supplemented with 0.1% decomplemented autologous serum, pre-stained with 1 µg/ml calcein/AM for 30 minutes at 37°C, and then incubated with 30 µg/ml of RITC-80 M or RITC-95 M for 3 hours at 37°C. PMNs were then centrifuged for 2 minutes at 1,500 g at room temperature and plated on a glass slide coated with 100% decomplemented autologous serum. Slides were coated with autologous serum that was prepared by centrifuging clotted blood for 15 minutes at 700 g at room temperature and decomplemented for 30 minutes at 56°C to avoid activation of PMNs by the glass surface of the slide. PMNs were visualized live at 37°C in an environment chamber with 5% CO₂ through a spinning disc confocal microscope equipped with a 63× objective (Quorum Spinning Disc Wave FX, ON, Canada). The index of internalization of chitosan was calculated as the percentage age of PMNs that internalized any visually detectable quantity of RITC-chitosan. One hundred cells were observed for each experimental condition.

Interaction of 80 M and 95 M chitosan with monocytes, granulocytes, and lymphocytes in whole blood

The interaction of RITC-80 M and RITC-95 M chitosan with blood cells was determined by flow cytometry. Blood samples were first treated to eliminate erythrocytes by lysis, as described by Desmeules and coworkers [22], and were then stimulated for 30 minutes at 37°C with 5 µg/ml RITC-80 M. Chitosan binding to cells was visualized using FACSscan flow cytometry. The binding index was calculated as fluorescence units of a cellular population incubated with RITC-80 M chitosan/fl uorescence units of a cellular population incubated in the same volume of the diluent (double-distilled water).

Statistical analysis

Results expressed as means ± standard error. Statistical analyses were performed using GraphPad Instat 3.0 (GraphPad Software, Inc., San Diego, CA, USA). Comparisons made between two groups were analyzed with the unpaired Student’s t-test. Comparisons made between two or more groups were analyzed by one-way analysis of variance and the Tukey-Kramer post hoc test. P < 0.05 was regarded to indicate statistical significance.

Results

The chemotactic effect of 80 M and 95 M chitosan on polymorphonuclear neutrophils

Before we conducted the study, we verified that we could reproduce the chemotactic activity of 80 M chitosan toward PMNs observed in vivo, in the cartilage repair model, with an in vitro chemotaxis assay. Briefly, isolated PMNs were labeled with calcein/AM and the chemotactic activity of 80 M chitosan was determined using the ChemoTx chemotaxis system – a transwell migration assay. We provide direct evidence that under our experimental conditions the 80 M chitosan preparation was chemotactic for PMNs (Figure 1).

Chitosan preparations composed of chitosan of varying degrees of DDA, greater than 80%, have been reported to be chemotactic for PMNs in vitro and in vivo [12]. It is not clear from these studies, however, whether the chemotactic activity of chitosan is dependent on the degree of DDA. To determine whether the chemotaxis of PMNs toward chitosan is dependent on the degree of DDA, a similar chemotaxis experiment was performed with 95 M chitosan. In contrast to 80 M chitosan, 95 M chitosan was not chemotactic for PMNs under the same experimental conditions (Figure 1). These results not only confirmed the potential of 80 M chitosan to attract PMNs but also indicated that the degree of acetylation of chitosan affected its chemotactic activity toward PMNs.

Mediator(s) of the chemotactic effect of 80 M and 95 M chitosan on polymorphonuclear neutrophils

We then investigated the molecular mechanism through which 80 M chitosan induces chemotaxis of PMNs. Because neutrophils are a major source of the strong chemotactic mediators leukotriene B₄ (LTB₄) and platelet-activating factor (PAF), we studied the activation of this metabolic pathway in response to 80 M chitosan. LTB₄ is generated by the oxygenation of arachidonic acid by a 5-lipoxygenase. Arachidonic acid becomes available to 5-lipoxygenase once it is released from 1-O-alkyl-2-acyl-glycerophosphocholine by cytosolic phospholipase A₂ (cPLA₂-α) that also releases lyso-PAF simultaneously [23]. To determine whether these phospholipid-derived metabolites are responsible for the chemotactic activity of 80 M chitosan toward human PMNs, the effect of pyrrolidine-1, an inhibitor of cPLA₂-α, on the chemotaxis of PMNs induced by 80 M chitosan was determined. Briefly, PMNs were pre-incubated with pyrrolidine-1 and then allowed...
to migrate toward 80 M chitosan. Pyrrolidine-1 decreased the chemotaxis of PMNs toward 80 M chitosan by 50% (Figure 2). These findings indicate that arachidonic acid metabolites are responsible, at least in part, for the chemotactic activity of 80 M chitosan toward PMNs. As a general rule, PMN chemotactic factors (for example, fMLP, interleukin-8, PAF, and LTB4) bind G-protein-coupled receptors. The activation of these G-protein-coupled receptors can be inhibited by pertussis toxin. We provide direct evidence that pertussis toxin significantly inhib-
To determine whether 80 M and 95 M chitosan induce PMNs to degranulate, the release of the contents of the primary and secondary granules was determined by measuring the amount of MPO and lactoferrin released. When incubated with 10 to 100 μg/ml 80 M or 95 M chitosan, the amounts of MPO and lactoferrin released into the media by PMNs were negligible (Figure 4). Together, the above observations indicate that the effects of 80 M chitosan on PMNs are not associated with the release of granule substances from PMNs.

The interaction of 80 M and 95 M chitosan with polymorphonuclear neutrophils

The difference in chemotactic activity between 80 M and 95 M chitosan toward PMNs may be due to the inability of PMNs to bind and/or internalize 95 M chitosan. The binding and internalization of RITC-80 M and RITC-95 M chitosan by PMNs was investigated by live cell confocal microscopy. Live cell imaging revealed that PMNs internalized both RITC-80 M and RITC-95 M chitosan in the presence of decomplemented serum, although internalization was much greater for fluorescent zymosan under similar conditions (Figure 5).

Because all of the white blood cells are present at the microcrack sites and could be involved in the effects of chitosan on cartilage repair and wound healing, we also investigated the ability of 80 M chitosan to interact with other leukocytes. To observe the interaction of 80 M chitosan with leukocytes with the same differential ratio in which these cells normally coexist, this analysis was performed in whole blood devoid of erythrocytes. Flow cytometry analysis of leukocytes in whole blood revealed that a greater amount of RITC-80 M chitosan associates with monocytes than granulocytes and lymphocytes (Figure 6a). Confocal microscopy revealed that monocytes readily internalize large amounts of RITC-80 M and RITC-95 M chitosan (Figure 6b).

Discussion

Novel therapeutic modalities that promote cartilage regeneration have the potential to delay significantly the progression of OA in patients who develop focal lesions. We therefore investigated some of the molecular mechanisms involved in the clinically beneficial effects of 80 M chitosan, which was recently shown to promote cartilage regeneration in both large and small animal cartilage repair models [2,3]. In recent years, evidence has accumulated that the PMN is more than just a leukocyte that phagocytoses foreign antigens. PMNs differentiate into dendritic cells [24] and have the capacity to modulate the adaptive immune response. The PMN therefore adopts different phenotypes that are determined by its environment. In this light, the response of PMNs to 80 M chitosan was investigated to identify the characteristics of the phenotype of PMNs that promotes cartilage regeneration. We report that 80 M chitosan selectively activates a subset of PMN functional responses.

The distinct phenotype of PMNs in response to 80 M chitosan is characterized by PMN chemotaxis and the absence of the production of superoxide and degranulation. In comparison, fMLP, a bacterial-derived peptide, is not only chemotactic for PMNs but also stimulates them to produce superoxide and degranulate. These observations strongly suggest that the PMN phenotype in the presence of 80 M chitosan promotes repair due, at least in part, to the lack of superoxide production and PMN degranulation. Our data agree with a recent report indicating that water-soluble chitosan oligomers suppress the

![Figure 3](image-url)
capacity for PMNs to respond to phorbol myristate acetate [16].

Because 80 M chitosan is chemotactic for PMNs, it must interact at the surface of PMNs to elicit a chemotactic response. The majority of chemotactic factors mediate their effect through G-protein-coupled receptors. To determine whether this applies to 80 M chitosan, we assessed the effect of pertussis toxin on 80 M chitosan-induced chemotaxis of PMN.

Pertussis-toxin inhibited PMN chemotaxis by 80%, implicating a G-protein-coupled receptor. The mechanism through which 80 M chitosan activates a G-protein-coupled receptor remains to be determined. It was previously found that conditioned media from canine PMNs stimulated with >80% DDA chitosan particles promoted chemotaxis of neutrophils [14]. We provide evidence, using a specific cPLA$_2$-α inhibitor, that phospholipid-derived mediators, possibly the chemotactic factors LTB$_4$ and PAF, are involved in the direct chemotactic activity...
of human PMNs toward a pure and sterile 80 M chitosan preparation. This is the first study to demonstrate that such lipid mediators contribute to half of the chemotactic activity of human PMNs toward chitosan. The cPLA₂-α inhibitor pyrrolidine-1 inhibited the chemotaxis of PMNs by 50%. Moreover, the inhibition of chemotaxis by 80% in the presence of pertussis toxin suggests that additional chemotactic agents acting through G-protein-coupled receptors participate in the chemotaxis of PMNs toward chitosan. Further investigation is required to characterize fully the molecular mechanisms that are involved in 80 M chitosan-induced chemotaxis of human PMNs.

Having characterized the response of PMNs toward 80 M chitosan, we conducted similar experiments with 95 M chitosan because we had observed a distinct response of PMNs toward 95 M chitosan in vivo. This is the first report on the effect of 95 M chitosan on PMN effector functions. Chitosan 95 M (95% glucosamine, 5% N-acetyl glucosamine) was unable to induce chemotactic activity, superoxide production, or the release of granule contents by PMNs. The lack of chemotactic activity of 95 M chitosan toward PMNs was not due to an effect on the viability of PMNs (data not shown). The percentage DDA of chitosan is therefore a determining factor for

The internalization of chitosan by PMNs. Freshly isolated polymorphonuclear neutrophils (PMNs) were resuspended in RPMI 1640 supplemented with 0.1% decomplemented fetal bovine serum, pre-stained with 1 μg/ml calcein-AM for 30 minutes at 37°C and incubated with 100 μg/1 × 10⁶ cells rhodamine B isothiocyanate (RTIC)-zymosan for 1.5 hours (a positive control), 15 μg/ml RTIC-80% deacetylated (80 M) or RTIC-95% deacetylated (95 M) chitosan for 3 hours at 37°C. PMNs were then centrifuged and plated on a slide coated with 100% decomplemented autologous serum and visualized by live confocal microscopy. The index of internalization of chitosan by PMNs was calculated as the percentage of cells that internalized RTIC-chitosan. Results are presented as mean ± standard error. This figure represents the results of three independent experiments.

The interaction of chitosan with monocytes, granulocytes, and lymphocytes in whole blood. (a) Whole blood was incubated for 30 minutes with 5 μg/ml rhodamine B isothiocyanate (RTIC)-80% deacetylated (80 M) chitosan at 37°C for 30 minutes before analysis by flow cytometry. The binding index was calculated as fluorescence units of each leukocyte population incubated with RITC-80 M chitosan/fluorescence units of leukocyte population in the absence of RITC-chitosan. Results are presented as mean ± standard error. *P < 0.05 versus autofluorescence for each leukocyte population. (b) Macrophages were seeded on glass slides (2 × 10⁶ cells/ml) in RPMI 1640 supplemented with 0.1% decomplemented fetal bovine serum, pre-stained with 1 μg/ml calcein AM for 30 minutes at 37°C, and incubated with 100 μg/1 × 10⁶ cells RTIC-zymosan for 1.5 hours (a positive control), 15 μg/ml RTIC-80 M, or RTIC-95% deacetylated (95 M) chitosan for 3 hours at 37°C. Macrophages were then visualized live through a spinning disc confocal microscope with a 63x objective. The top panels are images taken in the X-Y plane and the lower panels are images taken in the X-Z plane. This figure represents the results of three independent experiments.
the activation of PMNs by chitosan and potentially for the therapeutic use of chitosan. Our findings indicate that chitosans in the range from 80% to 95% DDA can elicit quite different biologic responses, and highlight the importance of defining the DDA level when conducting biologic assays. Some of the differential responses could be related to the very low solubility of 95% DDA chitosan at neutral pH [8]. In the light of these findings, it is of interest to investigate fully the effect of chitosan with other percentages of DDA on PMNs to determine whether there is a percentage DDA that induces maximal chemotactic activity in PMNs and consequently an optimal therapeutic effect.

Another parameter that may modify the response of PMNs to chitosan is the form in which the chitosan is used. VanderVord and coworkers [6] reported that a chitosan scaffold made with chitosan of 92% DDA is chemotactic for PMN in vivo. Because 92% DDA chitosan is structurally more similar to 95 M than to 80 M chitosan, our data indicate that PMN migration to 92% DDA chitosan should be quite modest. The discrepancy between this previous observation and our findings could potentially be explained by the fact that the scaffold used in the in vivo study was prepared by coating polytetrafluoroethylene tubes with 92% DDA chitosan, and did not employ pure chitosan. It will be of therapeutic interest to determine how differently PMNs react to chitosans of the same percentage DDA of different structural forms – suspension versus scaffold.

It is generally accepted that PMN phagocytose chitosan, but no microscopy studies have been performed to demonstrate that PMNs indeed internalize chitosan. This is a relevant question because PMNs can respond to foreign material without necessarily internalizing it. We provide direct evidence that PMNs can internalize 80 M chitosan without stimulating degranulation. Around 10% of PMNs internalized 80 M chitosan, in the presence of 0.5% heat-inactivated serum. These observations are quite different to those in PMN and monosodium urate crystals, which have a poor capacity for internalization while strongly activating PMNs, probably because of an autocrine effect [25]. It is highly likely that lipid mediators are involved in this autocrine effect. In our internalization assay, PMNs readily internalized zymosan, a yeast cell wall preparation that activates neutrophils. Because both 95 M and 80 M were internalized without activating neutrophils, our data demonstrate that internalization of a polysaccharide biomaterial does not automatically trigger degranulation.

Recently, PMNs were reported to express the mannose receptor [26], a receptor that is implicated in the internalization of chitosan by macrophages [27,28]. We provide evidence that monocytes internalize 80 M chitosan more readily than PMNs, suggesting that the molecular mechanisms involved in the internalization of 80 M chitosan by PMNs differ from those of macrophages. This does not imply a less important role of PMNs in chitosan-based wound healing. PMNs usually out-number macrophages in certain phases of wound healing and can collectively synthesize large quantities of soluble mediators.

**Conclusions**

In summary, 80 M chitosan is chemotactic for human PMNs but does not activate additional PMN effector functions such as degranulation and superoxide production. Because the beneficial therapeutic effects of 80 M chitosan are preceded by the recruitment of a significant number of PMNs, this chitosan-induced PMN phenotype could be associated with promotion of repair. Our observations also indicate that the degree of deacetylation is an important factor to consider in the use of chitosan as an accelerator of repair because PMNs exhibit a differential capacity to migrate towards 80 M and 95 M chitosan.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

PS and HG made equal contributions to the experimental aspects of this study. They performed the majority of the experiments. SM and DR made important contributions to the conduct of certain experiments as well as the interpretation of the data. MF, PP, and CH contributed to the design of the experiments and the interpretation of the data. MF wrote the manuscript, and PP and CH revised it. All the experiments were performed and supervised in MF’s laboratory. HEG contributed to the interpretation of the data.

**Acknowledgements**

This research was funded by a Discovery Advancement Program grant awarded by the Canadian Arthritis Network to CDH, MJGF, PEP, and HEG. PS is a recipient of a scholarship awarded by the Canadian Arthritis Network, MJGF received a salary award from The Arthritis Society, and CDH received a salary award from the Fonds de la Recherche Santé Québec. We should like to thank Dr Matthew Shive for insightful comments and critical reading of the manuscript.

**References**

1. Felson DT: An update on the pathogenesis and epidemiology of osteoarthritis. *Radiol Clin North Am* 2004, 42:1-9.
2. Hoemann CD, Hurtig M, Rossomacha E, Sun J, Chevrier A, Shive MS, Buschmann MD: Chitosan-glycerol phosphate/blood implants improve hyaline cartilage repair in ovine microfracture defects. *J Bone Joint Surg Am* 2005, 87:2671-2686.
3. Hoemann CD, Sun J, Mckee MD, Chevrier A, Rossomacha E, Rivard GE, Hurtig M, Buschmann MD: Chitosan-glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defects. *Osteoarthritis Cartilage* 2007, 15:78-89.
4. Shive MS, Hoemann CD, Restrepo A, Hurtig MB, Duval N, Ranger P, Stannish W, Buschmann MD: BST-CerGel: in situ chondroinduction for cartilage repair. *Operative Tech Orthopaedics* 2006, 16:271-278.
5. Onishi H, Machida Y: Biodegradation and distribution of water-soluble chitosan in mice. *Biomaterials* 1999, 20:175-182.
6. VanderVord PJ, Matthew HWT, DeSilva SP, Mayton L, Wu B, Wooley PH: Evaluation of the biocompatibility of a chitosan scaffold in mice. *J Biomed Mater Res* 2002, 59:585-590.
7. Malette WG, Quigley HJ, Gaines RD, Johnson ND, Rainer WG: Chitosan – a new hemostatic. *Ann Thorac Surg* 1983, 36:55-58.

8. Varum KM, Holme HK, Izume M, Stokke BT, Smidsrod O: Determination of enzymatic hydrolysis specificity of partially N-acetylated chitosans. *Biochim Biophys Acta* 1996, 1291:5-15.

9. Sashiwa H, Saimoto H, Shigemasa Y, Ogawa R, Tokura S: Lysozyme susceptibility of partially decetylated chitin. *Int J Biol Macromol* 1990, 12:295-296.

10. Tomihata K, Ikada Y: In vitro and in vivo degradation of films of chitin and its decetylated derivatives. *Biomaterials* 1997, 18:567-575.

11. Chevrier A, Hoemann CD, Sun J, Buschmann MD: Chitosan-glycerophosphate/blood implants increase cell recruitment, transient vascularization and subchondral bone remodeling in drilled cartilage defects. *Osteoarthritis Cartilage* 2007, 15:318-327.

12. Usami Y, Okamoto Y, Minami S, Matsuhashi A, Kumazawa NH, Tanikawa S, Shigemasa Y: Migration of canine neutrophils to chitin and chitosan. *J Vet Med Sci* 1994, 56:1215-1216.

13. Usami Y, Okamoto Y, Minami S, Matsuhashi A, Kumazawa NH, Tanikawa S, Shigemasa Y: Chitin and chitosan induce migration of bovine polymorphonuclear cells. *J Vet Med Sci* 1994, 56:761-762.

14. Usami Y, Okamoto Y, Takayama T, Shigemasa Y, Minami S: Chitin and chitosan stimulate canine polymorphonuclear cells to release leukotriene B-4 and prostaglandin E-2. *J Biomed Mater Res* 1998, 42:517-522.

15. Enjo H, Yamada H, Tanaka I, Kaba N, Matsuura M, Okumura M, Kadosawa T, Fujinaga T: Accelerating effects of chitosan for healing at early phase of experimental open wound in dogs. *Biomaterials* 1999, 20:1407-1414.

16. Dou JL, Tan CY, Du YG, Bai XF, Wang KY, Ma XJ: Effects of chitooligosaccharides on rabbit neutrophils in vitro. *Carbohydr Polym* 2007, 69:209-213.

17. Ma O, Lavertu M, Sun J, Nguyen S, Buschmann MD, Winnik FM, Hoemann CD: Precise derivatization of structurally distinct chitosans with rhodamine B isothiocyanate. *Carbohydr Polym* 2008, 72:616-624.

18. Fernandes MJ, Rollet-Labelle E, Pare G, Marois S, Tremblay ML, Teillaud JL, Naccache PH: CD16b associates with high-density, detergent-resistant membranes in human neutrophils. *Biochem J* 2006, 393:351-359.

19. Gilbert C, Levasseur S, Desaulniers P, Burgess SG, Naccache PH: Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. *J Immunol* 2003, 170:5235-5243.

20. Bradley PP, Priebat DA, Christensen RD, Rothstein G: Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. *J Invest Dermatol* 1982, 78:206-209.

21. Mocsai A, Ligeti E, Lowell CA, Berton G: Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. *J Immunol* 1999, 162:1120-1126.

22. Bernades P, Dufour M, Fernandes MJ: A rapid flow cytometry assay for the assessment of calcium mobilization in human neutrophils in a small volume of lysed whole-blood. *J Immunol Methods* 2009, 340:154-157.

23. Bauldry SA, Wooten RE: Leukotriene B4 and platelet activating factor production in permeabilized human neutrophils: role of cytosolic PLA2 in LTB4 and PAF generation. *Biochim Biophys Acta* 1996, 1303:63-73.

24. Iking Konert C, Cseko C, Wagner C, Stegmaier S, Andrassy K, Hansch GM: Transdifferentiation of polymorphonuclear neutrophils: acquisition of CD83 and other functional characteristics of dendritic cells. *J Mol Med* 2004, 79:464-474.

25. Desaulniers P, Fernandes M, Gilbert C, Bourgois SG, Naccache PH: Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals. *J Leukoc Biol* 2001, 70:859-868.

26. Valera I, Vigo AG, Alonso S, Barbolla L, Crespo MS, Fernandez N: Peptidoglycan and mannose-based molecular patterns trigger the arachidonic acid cascade in human polymorphonuclear leukocytes. *J Leukocyte Biol* 2007, 81:925-933.